Jagsonpal Pharmaceuticals share news, announcements and annual reports
NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap
Jagsonpal Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹216.09down ₹5.85 (2.64%)BSE ₹216.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹221.94.
30 Oct: open ₹222.00, high ₹226.64, low ₹212.58
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,427 Cr1,360th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 31.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 5.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.85%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 71,54749.3% delivered
Jagsonpal Pharmaceuticals share news and announcements
550 announcements, routine notices left out, newest first. Page 8 of 11.
Sep 2019
Aug 2019
19 Aug · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.13 Aug · Results
13 Aug · Board meeting
1 Aug · Board meeting
Jul 2019
Jun 2019
May 2019
28 May · Board meeting
28 May · Results
Apr 2019
Feb 2019
13 Feb · Results
13 Feb · Board meeting
4 Feb · Board meeting
Nov 2018
14 Nov · Board meeting
14 Nov · Results
Oct 2018
Sep 2018
28 Sep · Meeting
Aug 2018
9 Aug · Board meeting
9 Aug · Results
1 Aug · Board meeting
Jun 2018
1 Jun · Legal
Exchange has sought clarification from Jagsonpal Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
May 2018
30 May · Board meeting
30 May · Results
17 May · Board meeting
Apr 2018
Feb 2018
9 Feb · Results
Dec 2017
13 Dec · Committee Meeting Updates
12 Dec · Results
4 Dec · Board meeting
Inter-alia, to consider and approve the Unaudited Financial Results (Standalone) for the second quarter ended September 30, 2017. This information is also be available on the Company's website at www.jagsonpal.com
Oct 2017